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ABSTRACT
Objective: To investigate the role of radiotherapy (RT) in patients who underwent 
hysterectomy for uterine carcinosarcoma (UCS).
Methods: Patients with the International Federation of Gynecology and Obstetrics stage I–
IVa UCS who were treated between 1990 and 2012 were identified retrospectively in a multi-
institutional database. Of 235 identified patients, 97 (41.3%) received adjuvant RT. Twenty-
two patients with a history of previous pelvic RT were analyzed separately. Survival outcomes 
were assessed using the Kaplan-Meier method and Cox proportional hazards model.
Results: Patients with a previous history of pelvic RT had poor survival outcomes, and 72.6% 
of these patients experienced locoregional recurrence; however, none received RT after a 
diagnosis of UCS. Univariate analyses revealed that pelvic lymphadenectomy (PLND) and 
para-aortic lymph node sampling were significant factors for locoregional recurrence-free 
survival (LRRFS) and disease-free survival (DFS). Among patients without previous pelvic 
RT, the percentage of locoregional failure was lower for those who received adjuvant RT than 
for those who did not (28.5% vs. 17.5%, p=0.107). Multivariate analysis revealed significant 
correlations between PLND and LRRFS, distant metastasis-free survival, and DFS. In 
subgroup analyses, RT significantly improved the 5-year LRRFS rate of patients who did not 
undergo PLND (52.7% vs. 18.7% for non-RT, p<0.001).
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Clinical significance of radiotherapy 
in patients with primary uterine 
carcinosarcoma: a multicenter 
retrospective study (KROG 13-08)
Conclusion: Adjuvant RT decreased the risk of locoregional recurrence after hysterectomy for 
UCS, particularly in patients without surgical nodal staging. Given the poorer locoregional 
outcomes of patients previously subjected to pelvic RT, meticulous re-administration of RT 
might improve locoregional control while leading to less toxicity in these patients.
Keywords: Locoregional Control; Radiotherapy, Adjuvant; Uterine Carcinosarcoma
INTRODUCTION
Uterine carcinosarcoma (UCS), also known as malignant mixed Müllerian tumor, is a rare 
gynecologic malignancy with an annual incidence of less than two cases per 100,000 women 
in the United States. This aggressive type of tumor accounts for less than 5% of all uterine 
malignancies but more than 15% of all uterine cancer-associated deaths [1]. Patients with 
UCS have a poor prognosis, with 5-year survival rates of 35% to 39% [2,3].
Surgery is considered the standard treatment for UCS, and the current recommendation 
is hysterectomy with bilateral salpingo-oophorectomy (BSO), pelvic lymphadenectomy 
(PLND), and para-aortic lymph node (PALN) sampling with peritoneal washings, although 
the additive benefit of lymphadenectomy remains undetermined [4,5]. However, high rates of 
postoperative relapse and metastasis suggest the need for effective adjuvant therapies [6].
Adjuvant radiotherapy (RT), as a component of disease management, is known to improve 
locoregional control in patients with UCS, although its impact on survival remains 
controversial [6-9]. The limited availability of information regarding surgical staging and 
prognostic factors makes it difficult to draw conclusions from the current literature [7]. The 
purpose of the present study, therefore, was to investigate retrospectively the role of adjuvant 
RT in patients with UCS who underwent hysterectomy at multiple institutions.
MATERIALS AND METHODS
Patients with UCS who underwent hysterectomy at 11 institutions in Korea between 
January 1990 and December 2012 were enrolled. The inclusion criteria were: (1) patients 
with pathologically confirmed UCS; (2) adult women ≥20 years of age; (3) patients who 
underwent curative hysterectomy; and (4) stage I–IVa UCS according to the revised the 
International Federation of Gynecology and Obstetrics (FIGO) staging system [10]. Nodal 
metastasis was evaluated by surgical staging or via imaging techniques such as pelvic 
magnetic resonance imaging, abdomen-pelvic computed tomography, or positron emission 
tomography-computed tomography. Patients with distant metastasis, which was diagnosed 
via punch biopsy, or those who underwent brachytherapy without pelvic RT were excluded. 
Finally, 235 patients were included in the analysis. Information regarding patient and tumor 
characteristics, the extent of surgery, type of adjuvant treatment, and recurrence and survival 
were collected from a Korean multi-institutional retrospective database. This study was 
approved by the Korean Radiation Oncology Group (KROG 13-08) and the Institutional 
Review Boards of all participating hospitals.
All patients underwent hysterectomy with BSO. PLND and para-aortic lymph node 
sampling or dissection (PALND) were performed in 181 patients (77%) and 131 patients 
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(55.7%), respectively. Adjuvant RT was administered to 97 patients (41.3%). Because of the 
retrospective nature of this study, there were no specific patient selection criteria for RT or 
adjuvant treatment modalities. All 97 RT-treated patients received external-beam RT covering 
the vaginal vault and pelvic nodal area. Fourteen patients underwent RT that included the 
para-aortic nodal area, and eight underwent brachytherapy. The median external RT dose 
was 50.4 Gy, and the median brachytherapy dose was 20.5 Gy. Adjuvant chemotherapy 
was administered to 133 patients (56.6%), and the most commonly used regimen was a 
combination of ifosfamide and cisplatin. Twenty-two patients (9.4%) underwent pelvic RT 
for previous malignancies before receiving a diagnosis of UCS; none of these patients had 
received adjuvant RT as a treatment for UCS. We analyzed these patients separately because 
of the potential effects of prior malignancies on the study outcome.
Locoregional recurrence was defined as a recurrence in the pelvis, which included the 
vaginal vault, pelvic lymph node, and PALN areas. Locoregional recurrence-free survival 
(LRRFS), distant metastasis-free survival (DMFS), and disease-free survival (DFS) were 
defined respectively as the time from surgery to locoregional recurrence or death, to distant 
metastasis or death, and to disease recurrence or death. Overall survival (OS) was defined 
as the time from surgery to death, regardless of cause. In-field failure was defined as any 
recurrence within the radiation field.
The chi-square test was used to compare the categorical characteristics of patients who did 
and did not undergo RT. The t-test was used to compare age and tumor size. Survival rates 
were estimated using the Kaplan-Meier method. A univariate analysis based on the log-rank 
test was performed to identify prognostic factors affecting survival. A multivariate analysis 
was conducted using the Cox proportional hazard model. Factors with statistically significant 
probability values in the univariate analysis were included in the multivariate analysis. All 
statistical comparisons were two-sided, and p-values <0.05 were considered statistically 
significant.
RESULTS
1. Patient and tumor characteristics
A total of 213 patients had not previously undergone pelvic RT. The median patient age was 
58 years (range, 27 to 87 years). Nine patients (4.2%) had a history of tamoxifen use. PLND 
and PALND were performed in 173 patients (81.2%) and 126 (59.2%), respectively. Adjuvant 
RT was performed in 97 patients (45.5%), and adjuvant chemotherapy was administered to 
117 patients (54.9%). The median tumor size was 5 cm (range, 0 to 20 cm). Except for 22 
patients with missing information, 42 patients (22%) had developed pelvic node metastases. 
Twenty-four patients (14%) had PALN metastases. Eighteen patients (8.5%) had positive 
resection margins, and 75 (35.2%) exhibited lymphovascular space invasion (LVI). The 
clinicopathologic characteristics of patients treated and not treated with adjuvant RT are 
compared in Table 1. There were no significant differences between patients in the no RT 
and RT groups with respect to tamoxifen history, extent of lymph node dissection, tumor 
size, PALN metastasis status, FIGO stage, resection margin status, and LVI status. A higher 
percentage of patients in the no RT group underwent adjuvant chemotherapy (63.8% vs. 
44.3%, p=0.004), and lower percentages of patients in this group exhibited pelvic node 
metastasis (15.5% vs. 24.7%, p=0.074) and LVI (31% vs. 40.2%, p=0.056).
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The characteristics of patients with a previous history of pelvic RT are also described in Table 
1. PLND and PALND were performed in eight patients (36.4%) and five (22.7%), respectively. 
Adjuvant chemotherapy was administered to 16 patients (72.7%). Two patients (9.1%) and 
one (4.5%) exhibited pelvic node and PALN metastasis, respectively. Eleven patients (50%) 
had positive resection margins, and 12 (54.5%) had LVI. Characteristics of these patients’ 
prior malignancies are described in Table 2.
2. Patterns of failure
The median follow-up duration of patients without a history of previous pelvic RT, calculated 
from the date of surgery, was 25 months (range, 0.5 to 273 months). Eighty-six patients 
(40.4%) had developed recurrences by the time of the analysis. Locoregional recurrence, 
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Table 1. Patient characteristics
Characteristic No RT (n=116) RT (n=97) p-value Previous pelvic RT history (n=22)
Age at diagnosis (yr) 0.108
<60 59 (50.9) 60 (61.9) 5 (22.7)
≥60 57 (49.1) 37 (38.1) 17 (77.3)
Tamoxifen history 0.156
No 109 (94.0) 94 (96.9) 21 (95.5)
Yes 7 (6.0) 2 (2.1) 0
Unknown 0 1 (1.0) 1 (4.5)
Pelvic lymphadenectomy 0.956
No 21 (18.1) 18 (18.6) 14 (63.6)
Yes 94 (81.0) 79 (81.4) 8 (36.4)
Unknown 1 (0.9) 0 0
PALND 0.463
No 50 (43.1) 37 (38.1) 17 (77.3)
Yes 66 (56.9) 60 (61.9) 5 (22.7)
Tumor size (cm) 0.246
≤6 61 (52.6) 60 (61.9) 6 (27.3)
>6 47 (40.5) 33 (34) 13 (59.1)
Unknown 8 (6.9) 4 (4.1) 3 (13.6)
Pelvic node metastasis 0.074
No 87 (75.0) 62 (63.9) 14 (63.6)
Yes 18 (15.5) 24 (24.7) 2 (9.1)
Unknown 11 (9.5) 11 (11.4) 6 (27.3)
Para-aortic node metastasis 0.781
No 78 (67.3) 69 (71.1) 15 (68.2)
Yes 12 (10.3) 12 (12.4) 1 (4.5)
Unknown 26 (21.4) 16 (16.5) 6 (27.3)
FIGO stage 0.267
I 71 (61.2) 49 (50.5) 6 (27.3)
II 11 (9.5) 10 (10.3) 5 (22.7)
III 31 (26.7) 37 (38.2) 9 (40.9)
IVA 3 (2.6) 1 (1.0) 2 (9.1)
Resection margin 0.652
Negative 95 (81.9) 76 (78.3) 7 (31.8)
Positive 9 (7.8) 9 (9.3) 11 (50.0)
Unknown 12 (10.3) 12 (12.4) 4 (18.2)
LVI 0.056
No 50 (43.1) 29 (29.9) 4 (18.2)
Yes 36 (31.0) 39 (40.2) 12 (54.5)
Unknown 30 (25.9) 29 (29.9) 6 (27.3)
Chemotherapy 0.004
No 42 (36.2) 54 (55.7) 6 (27.3)
Yes 74 (63.8) 43 (44.3) 16 (72.7)
Values are presented as number (%).
FIGO, the International Federation of Gynecology and Obstetrics; LVI, lymphovascular space invasion; PALND, para-aortic lymph node sampling or dissection; RT, 
radiotherapy.
distant metastasis, and both locoregional and distant failure occurred in 34 patients (16%), 
36 (16.9%), and 16 (7.5%), respectively. Forty-four patients (37.9%) in the no RT group and 42 
(43.3%) in the RT group developed recurrent disease. In the no RT group, 32 patients (28.5%) 
and 19 (16.4%) developed locoregional recurrences and distant metastases, respectively (Fig. 
1A). In the RT group, 17 patients (17.5%) and 33 (34.1%) developed locoregional recurrences and 
distant metastases (Fig. 1B), respectively, and nine patients (9.3%) experienced in-field failure.
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Table 2. Characteristics related to previous malignancies in patients who underwent pelvic RT history (n=22)
Characteristic Value
Months between RT and UCS diagnosis (mo) 123.6 (46.3–293.5)
Type of malignancy
Uterine cervix 15 (68.2)
Rectum 7 (31.8)
Stage of malignancy
I 3 (13.6)
II 8 (36.4)
III 7 (31.8)
Unknown 4 (18.2)
Surgical procedure for malignancy
No 12 (54.5)
Yes 10 (45.5)
Treatment
External RT 6 (27.3)
External RT followed by brachytherapy 13 (59.1)
Unknown 3 (13.6)
RT field
Pelvis 16 (72.8)
Semi-extended 1 (4.5)
Unknown 5 (22.7)
RT dose (Gy) 75 (34–93)
CCRT
No 13 (59.1)
Yes 6 (27.3)
Unknown 3 (13.6)
Values are presented as median (range) or number (%).
CCRT, concurrent chemoradiotherapy; RT, radiotherapy; UCS, uterine carcinosarcoma.
Local failure
No RT
No recurrence 72 (62.1%)
RT
No recurrence 55 (56.7%)
Prior pelvic RT
No recurrence 4 (18.2%)
Regional failure Distant failure
11
(9.5%)
9
(7.8%)
4
(3.4%)
3
(2.6%)
11
(9.5%)
1
(0.9%)
5
(4.3%)
Local failure
Regional failure Distant failure
4
(4.1%)
4
(4.1%)
5
(5.2%)
3
(3.1%)
25
(25.8%)
0
(0%)
1
(1%)
Local failure
Regional failure Distant failure
8
(36.4%)
1
(4.5%)
3
(13.6%)
1
(4.5%)
2
(9.1%)
0
(0%)
3
(13.6%)
A B C
Fig. 1. Patterns of failure. (A) The no radiotherapy (RT) group, comprising patients with no previous history of pelvic RT. Thirty-two patients (28.5%) in this 
group developed locoregional recurrence. (B) The RT group, comprising patients with no previous history of pelvic RT. Seventeen patients (17.5%) in this group 
developed locoregional recurrences. (C) Patients with a previous history of pelvic RT. Sixteen patients (72.6%) in this group developed locoregional recurrences.
The median follow-up duration of patients with a history of previous pelvic RT, calculated 
from the date of surgery, was 13.5 months (range, 1 to 92 months). Eighteen patients (71.8%) 
had developed recurrences by the time of the analysis. Locoregional recurrences and distant 
metastases were observed in 16 patients (72.6%) and six (27.2%), respectively (Fig. 1C).
3. Survival outcomes and analysis of prognostic factors
During the follow-up period, the 5-year LRRFS, DMFS, DFS, and OS rates of patients 
without a history of previous pelvic RT were 56.8%, 58.4%, 52.4%, and 67%, respectively; 
the corresponding 2-year rates of patients with a history of previous pelvic RT were 10.8%, 
29.7%, 10.8%, and 44.3%, respectively.
Univariate analyses of the LRRFS, DMFS, DFS, and OS of patients without a history of 
previous pelvic RT were conducted, and the results of each Kaplan-Meier survival analysis are 
shown in Supplementary Fig. 1 (A, LRRFS; B, DMFS; C, DFS; D, OS).
A lack of PLND, a lack of PALND, large tumor size, higher FIGO stage, pelvic node 
metastasis, PALN metastasis, positive resection margin, and LVI correlated significantly with 
reduced LRRFS. In the multivariate analysis, PLND was the only significant factor associated 
with LRRFS (hazard ratio [HR], 0.366; 95% CI, 0.163 to 0.820; p=0.015) (Table 3). Adjuvant 
RT had no significant effect on LRRFS in these patients.
The factors significantly associated with reduced DMFS in the univariate analysis were a lack 
of PLND, large tumor size, higher FIGO stage, pelvic node metastasis, PALN metastasis, and 
LVI. Adjuvant chemotherapy had no significant effect on DMFS. A lack of PLND (HR, 0.401; 
95% CI, 0.187 to 0.860; p=0.019), higher FIGO stage (HR, 1.625; 95% CI, 1.045 to 2.527; 
p=0.031), and LVI (HR, 2.280; 95% CI, 1.134 to 4.583; p=0.021) remained significant in the 
multivariate analysis, whereas PALN metastasis exhibited borderline significance (HR, 2.297; 
95% CI, 0.995 to 5.303; p=0.051) (Table 3).
The factors significantly associated with DFS in the univariate analysis were the same as those 
significantly associated with LRRFS. In the multivariate analysis, PLND (HR, 0.318; 95% CI, 
0.148 to 0.684; p=0.003) and PALN metastasis (HR, 2.504; 95% CI, 1.008 to 6.220; p=0.048) 
retained significant associations with DFS (Table 3).
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Table 3. Survival outcomes according to the Cox proportional hazards multivariate model in patients without previous pelvic RT history
Variable LRRFS DMFS DFS OS
HR 95% CI p-value HR 95% CI p-value HR 95% CI p-value HR 95% CI p-value
PLND (no vs. yes) 0.366 0.163–0.820 0.015 0.401 0.187–0.860 0.019 0.318 0.148–0.684 0.003 - - -
PALND (no vs. yes) 0.493 0.217–1.120 0.091 - - - 0.614 0.280–1.348 0.224 - - -
Tumor size (cm) (≤6 vs. >6) 1.583 0.792–3.161 0.193 1.546 0.837–2.856 0.164 1.698 0.898–3.212 0.104 1.272 0.623–2.597 0.508
Pelvic node metastasis (no vs. yes) 0.926 0.328–2.612 0.884 0.488 0.193–1.232 0.129 0.834 0.316–2.198 0.713 0.421 0.145–1.216 0.110
Para-aortic node metastasis (no 
vs. yes)
1.381 0.506–3.769 0.529 2.297 0.995–5.303 0.051 2.504 1.008–6.220 0.048 1.162 0.436–3.100 0.764
FIGO stage (I–II vs. III–IVA) 1.156 0.677–1.972 0.595 1.625 1.045–2.527 0.031 1.189 0.728–1.941 0.489 1.647 0.994–2.729 0.053
Resection margin (negative vs. 
positive)
3.196 0.781–13.083 0.106 - - - 2.084 0.555–7.831 0.277 - - -
LVI (negative vs. positive) 1.976 0.891–4.381 0.094 2.280 1.134–4.583 0.021 1.647 0.804–3.377 0.173 3.497 1.489–8.214 0.004
RT (no vs. yes) 0.875 0.452–1.693 0.691 1.323 0.722–2.423 0.365 1.036 0.563–1.905 0.910 1.486 0.709–3.114 0.294
CI, confidence interval; DFS, disease-free survival; DMFS, distant metastasis-free survival; FIGO, the International Federation of Gynecology and Obstetrics; HR, 
hazard ratio; LRRFS, locoregional recurrence-free survival; LVI, lymphovascular space invasion; OS, overall survival; PALND, para-aortic lymph node sampling or 
dissection; PLND, pelvic lymphadenectomy; RT, radiotherapy.
Tumor size, pelvic node metastasis, PALN metastasis, FIGO stage III/IVa, and LVI were 
significantly associated with OS in the univariate analysis. However, only LVI remained 
significant in the multivariate analysis (HR, 3.497; 95% CI, 1.489 to 8.214; p=0.004), although 
an advanced FIGO stage exhibited borderline significance (HR, 1.647; 95% CI, 0.994 to 2.729; 
p=0.053) (Table 3). Neither adjuvant RT nor chemotherapy was associated with DFS or OS.
A univariate analysis of patients with previous pelvic RT showed that PLND and PALND were 
significant factors for LRRFS and DFS (Table 4). No other factors correlated significantly 
with DMFS or OS in this analysis.
4. Identification of UCS subgroups that might benefit from adjuvant RT
To identify patient subgroups that might benefit from adjuvant RT, we hypothesized that 
adjuvant RT could benefit patients with poor prognostic factors. Therefore, we performed 
subgroup analyses based on adjuvant RT and/or PLND statuses, as the latter was the only 
significant factor associated with LRRFS in the multivariate analysis. The 5-year LRRFS rates 
were 18.7% for the PLND–/RT– group (n=21), 52.7% for the PLND–/RT+ group (n=18), 64.8% 
for the PLND+/RT– group (n=94), and 58.8% for the PLND+/RT+ group (n=77; p<0.001, log-
rank test) (Fig. 2).
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Table 4. Univariate analysis of variables in patients with previous pelvic RT history (n=22)
Variable LRRFS DMFS DFS OS
2-Year rate (%) p-value 2-Year rate (%) p-value 2-Year rate (%) p-value 2-Year rate (%) p-value
Age at diagnosis (yr) 0.133 0.976 0.150 0.504
<60 20.0 20.0 20.0 60.0
≥60 7.5 28.0 7.5 35.6
Pelvic lymphadenectomy 0.033 0.684 0.039 0.682
No 0 17.0 0 48.5
Yes 29.2 29.2 29.2 42.9
PALND 0.007 0.098 0.007 0.279
No 0 12.9 0 34.4
Yes 50.0 50.0 50.0 75.0
Tumor size (cm) 0.665 0.863 0.727 0.567
≤6 0 20.0 20.0 40.0
>6 9.4 36.0 9.4 48.2
Pelvic node metastasis 0.404 0.909 0.401 0.600
No 15.4 30.8 15.4 52.7
Yes 0 0 0 0
Para-aortic node metastasis 0.508 0.987 0.507 0.814
No 14.3 28.6 14.3 46.9
Yes 0 0 0 0
FIGO stage 0.761 0.684 0.745 0.780
I–II 20.2 33.3 20.2 53.3
III–IVA 0 0 0 38.9
Resection margin 0.882 0.885 0.950 0.230
Negative 16.7 33.3 16.7 33.3
Positive 11.7 23.4 11.7 70.0
LVI 0.473 0.543 0.473 0.557
Negative 33.3 33.3 33.3 66.7
Positive 9.3 32.1 9.3 56.1
Chemotherapy 0.547 0.819 0.554 0.700
No 20.8 25.0 20.8 50.0
Yes 7.2 21.4 7.2 43.7
DFS, disease-free survival; DMFS, distant metastasis-free survival; FIGO, the International Federation of Gynecology and Obstetrics; LRRFS, locoregional 
recurrence-free survival; LVI, lymphovascular space invasion; OS, overall survival; PALND, para-aortic lymph node sampling or dissection; RT, radiotherapy.
DISCUSSION
Despite efforts to overcome the dismal outcomes of patients with UCS after surgery 
alone, the rarity of this disease has made it difficult to establish evidence of the efficacy of 
adjuvant treatment. We observed beneficial effect of RT on LRRFS in a subgroup analysis, 
in accordance with a number of previous studies. To date, two randomized trials have been 
conducted to evaluate the efficacy of adjuvant RT in UCS patients. The Gynecologic Oncology 
Group 150 phase III randomized trial compared whole abdominal irradiation versus 
cisplatin, ifosfamide, and mesna as adjuvant therapy in 232 patients with UCS [11]. Although 
the OS and recurrence rates did not differ significantly between the two groups, patients 
who underwent chemotherapy had fewer recurrences and better OS rates. The European 
Organization for the Research and Treatment of Cancer Gynaecological Cancer Group 
55874 study [12] compared adjuvant pelvic RT versus observation in patients with uterine 
sarcoma, including 91 patients with UCS. Although no survival benefit was associated with 
RT, a marked decrease in the locoregional failure rate was observed in patients with UCS, 
with local recurrence rates of 47% and 24% in the observation and RT arms, respectively. 
In addition, several retrospective single institutional studies [6,13,14] and large-scale 
nationwide database studies [15,16] have evaluated the impact of adjuvant RT on UCS. In 
most of these studies, adjuvant RT significantly reduced local failure, although OS and distant 
metastasis were not affected. Sampath and Gaffney [17] analyzed available prospective and 
retrospective data that addressed the role of adjuvant RT in all histologic types of uterine 
sarcoma and suggested that adjuvant RT reduced the local failure rate by 50% among cases of 
UCS, leiomyosarcoma, and endometrial stromal sarcoma.
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Fig. 2. Kaplan-Meier survival analyses of subgroups of patients without a previous history of pelvic radiotherapy 
(RT), classified according to pelvic lymphadenectomy (PLND) and adjuvant RT statuses. The 5-year locoregional 
recurrence-free survival rates were 18.7% for the PLND–/RT– group, 52.7% for the PLND–/RT+ group, 64.8% for 
the PLND+/RT– group, and 58.8% for the PLND+/RT+ group.
Imaging-based preoperative nodal staging is insufficient for the detection of 
micrometastasis, as upstaging frequently occurs after pathologic evaluation in clinically 
node-negative patients. Therefore, patients with UCS should be subjected to extensive 
surgical staging, which includes node dissection as well as hysterectomy. The impact of 
PLND with or without adjuvant RT has been investigated, and 2 retrospective analyses of 
patient data from the Surveillance, Epidemiology, and End Results (SEER) database have 
demonstrated the clinical benefits of adjuvant RT in UCS patients, especially those not 
subjected to PLND [5,18].
In addition to surgical nodal staging, LVI was strongly associated with progression-free 
survival and weakly associated with OS in a multi-institutional cohort study of 111 patients 
with early-stage UCS [19]. The Gynecology Oncology Group also found that LVI was 
predictive of recurrence [20]. In our study, LVI was a significant prognostic factor for LRRFS, 
DMFS, DFS, and OS in a univariate analysis of patients without previous pelvic RT and was 
significantly associated with poor OS in a multivariate analysis.
When compared with the no RT group, the RT group in the present study had similar 
LRRFS and DFS rates and a lower incidence of locoregional failure, despite having 
higher percentages of patients with nodal metastasis and LVI. Furthermore, adjuvant RT 
significantly improved LRRFS in subgroups that did not undergo PLND. Therefore, adjuvant 
RT might be useful for reducing the risk of locoregional recurrence in patients who do not 
undergo PLND.
The worse DMFS observed in patients who received RT relative to those who did not might 
be attributable to the higher rates of nodal metastasis and LVI in the former group. Moreover, 
significantly fewer patients in the RT group received chemotherapy. Several studies have 
assessed the usefulness of adjuvant chemotherapy for UCS in an attempt to reduce the 
high incidence of distant failure after treatment. A phase III randomized trial of adjuvant 
chemotherapy for patients with uterine sarcoma (SARCGYN study) found that a combination 
of doxorubicin, ifosfamide, and cisplatin increased DFS [21]; however, this study was 
discontinued early because of the unavailability of participants. A recent study suggested 
that UCS is a metaplastic form of endometrial carcinoma, the sarcomatous component of 
which represents a de-differentiation of the carcinomatous component [22]. Therefore, 
those currently conducting studies are advised to cautiously apply the results of previous 
studies involving patients selected according to the earlier definition of UCS. Clinical 
studies that evaluate chemotherapy specifically in patients with UCS are required. A review 
of the Cochrane database with respect to adjuvant chemotherapy for UCS indicated that 
combination chemotherapy regimens that include ifosfamide should be considered in cases 
involving advanced-stage disease or metastasis [23]. In our study, however, chemotherapy 
had no significant survival benefit.
Patients who did and did not undergo pelvic RT previously exhibited different failure 
patterns. For example, locoregional recurrence occurred in less than 30% of patients who did 
not receive pelvic RT previously and in 66.3% of patients who received pelvic RT previously, 
regardless of the presence of distant metastasis. In addition, positive resection margins were 
observed in 50% of patients who received pelvic RT previously, but only in 8.9% of those who 
did not receive pelvic RT previously. Furthermore, 36.4% and 22.7% of patients who received 
pelvic RT previously underwent PLND and PALND, respectively; these rates were less than 
half of the corresponding rates among patients who did not receive pelvic RT previously 
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(81.2% and 59.2%, respectively). These findings suggest a tendency toward less aggressive 
surgery for patients with a previous history of pelvic RT, which could increase the likelihood 
of surgical complications.
Very limited data were available regarding re-irradiation of the pelvic area for the treatment 
of gynecologic malignancies. A case report of a patient with recurrent endometrial cancer 
described favorable outcomes from re-irradiation via conformal RT [24], and another 
retrospective study that included four re-irradiated patients with recurrent cervical cancer 
reported one case of complete response, two cases of partial response, and one case of 
stable disease [25]. Both reports suggested that a sufficient radiation dose is required to 
achieve tumor control and therefore suggested that conformal RT and, to a greater extent, 
intensity-modulated radiotherapy (IMRT) could provide safer and more effective treatment 
[24,25]. Regarding complications, substantial grade 2 to 3 toxicities have been observed 
in re-irradiated patients [25]. Comparative studies of the dose parameters, outcomes, and 
complications of postoperative IMRT and conventional or three-dimensional conformal 
RT for gynecologic cancers demonstrated significant reductions in toxicities without 
compromising clinical outcomes [26-29]. Therefore, IMRT should be considered for these 
patients in order to reduce toxicity while improving locoregional control.
Our study had several limitations in addition to its retrospective nature. First, information 
about treatment-related toxicities was lacking. Second, complete data were not available 
for all patients. Third, differences in the percentages of patients who received adjuvant 
chemotherapy and chemotherapy regimens were observed between the RT and no RT groups; 
these differences complicated our analyses and precluded an additional analysis of the effects 
of chemotherapy. Despite these limitations, our study provides valuable information about 
treatment outcomes in patients treated for UCS during the past 20 years, and has identified 
prognostic factors in a relatively large number of patients with this rare disease.
In conclusion, adjuvant RT reduced the rate of locoregional recurrence in patients with 
UCS. The eradication of occult micrometastasis in lymph nodes via PLND is presumably 
a mandatory step toward improved survival in patients with UCS. In cases involving 
hysterectomy without surgical nodal staging, adjuvant RT should be considered a viable 
means of reducing locoregional recurrence. Finally, the re-administration of RT to the 
pelvic area might improve locoregional control even in patients with a history of pelvic RT 
prior to the UCS diagnosis and less extensive surgical staging, as these patients had poorer 
locoregional outcomes when compared to patients without previous pelvic RT; however, 
further studies are required to confirm this finding.
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